Polish Journal of Pathology
eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
Share:
Send email
Share:
abstract:
Original paper

TROP-2 expression in triple-negative and human epidermal growth facto r recepto r 2 enriched breast cancers and its relationship with clinicopathologic parameters

Hale Kivrak
1
,
Duygu Turkbey Simsek
1
,
Egemen Akincioglu
1
,
Ilke Evrim Seçinti
2
,
Gül Sema Yildiran Keskin
3
,
Ismail Erturk
3
,
Murat Demiriz
1

  1. Department of Pathology, Gülhane Research and Training Hospital, University of Health Sciences, Ankara, Turkey
  2. Department of Pathology, Silifke State Hospital, Silifke/Mersin, Turkey
  3. Department of Medical Oncology, Gülhane Research and Training Hospital, University of Health Sciences, Ankara, Turkey
Pol J Pathol 2025; 76 (3)
DOI: https://doi.org/10.5114/pjp.2025.156555
Online publish date: 2025/11/28
View full text Get citation
 
PlumX metrics:
TROP-2 is a transmembrane calcium signaling molecule that is detected at a high rate (63%) in breast cancers. There are conflicting data on its relationship with subtypes, clinical, and pathological data in breast cancer.

TROP-2 expression levels were evaluated by immunohistochemistry, and the H-score method was used to analyze the data. This evaluation was conducted on a total of 79 patients diagnosed with triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2 (HER2) positive (HER2-E) breast cancer. The study also investigated the relationship between TROP-2 expression levels and the clinical-pathological features observed in patients diagnosed with TNBC and HER2-E. A total of 62 TNBC (78.5%) and 17 HER2-E (21.5%) cases were analyzed in the study.

The presence of high TROP-2 (H-score > 100) was detected in 87% of the TNBC group and 94% of the HER2-E group.

Among the pathological parameters, only low H-score values were found to have a statistically significant correlation with mucinous morphology; however, no significant correlation was found with other pathological parameters, including CerbB2 expression status. No significant relationship was found between H-score and clinical parameters. Furthermore, TROP-2 expression in HER2-E cancers is notably elevated. Further studies with larger series are required to clarify expression rates in mucinous tumors.
keywords:

breast cancer, immunohistochemistry, TROP-2, Sacituzumab govitecan
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.